Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
MENLO PARK, Calif., July 24, 2017 -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its Second Quarter 2017 Financial Results on Wednesday, August 2, 2017, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: August 2, 2017
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Audience Passcode: 6134-5895
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Contact: Pacific Biosciences Trevin Rard 650.521.8450 [email protected]
